Frithz G, Aström B, Dahlöf B, Hansson L, Tollin C, Himanen P, Sundstedt C D
Department of Medicine at Eskilstuna, Sweden.
Am J Med. 1989 Apr 17;86(4A):115-8. doi: 10.1016/0002-9343(89)90204-0.
Isradipine is a new calcium antagonist of the dihydropyridine type with marked vasodilator activity and minimal negative inotropic effects. It is a potent antihypertensive drug when given as monotherapy. This was a randomized double-blind crossover study of 16 weeks' duration, including 80 hypertensive patients with diastolic blood pressures of at least 95 mm Hg who had shown clinically relevant antihypertensive responses, but no normalization of blood pressure during pindolol 10 to 15 mg once daily as monotherapy. Either isradipine or placebo was added to the beta-blocker at doses of either 2.5 mg or 5 mg twice daily, which was doubled after four weeks if the diastolic blood pressure remained more than 90 mm Hg. The addition of isradipine (in either dose regimen) caused a pronounced reduction of blood pressure with no changes in heart rate. Five patients were withdrawn from the study because of adverse events while receiving isradipine compared with three taking placebo. A further three patients withdrew from the study because of adverse events (one patient) or lack of efficacy (two patients) during placebo treatment. These results indicate that isradipine is an effective and well-tolerated adjunct to beta-blockers in hypertensive patients.
伊拉地平是一种新型二氢吡啶类钙拮抗剂，具有显著的血管舒张活性和最小的负性肌力作用。作为单一疗法使用时，它是一种有效的降压药。这是一项为期16周的随机双盲交叉研究，纳入了80名舒张压至少为95mmHg的高血压患者，这些患者在每日一次服用10至15mg吲哚洛尔作为单一疗法时显示出临床相关的降压反应，但血压未恢复正常。将伊拉地平或安慰剂以每日两次2.5mg或5mg的剂量添加到β受体阻滞剂中，如果四周后舒张压仍高于90mmHg，则剂量加倍。添加伊拉地平（两种剂量方案中的任何一种）均导致血压显著降低，心率无变化。与三名服用安慰剂的患者相比，有五名患者在接受伊拉地平治疗期间因不良事件退出研究。另外三名患者在安慰剂治疗期间因不良事件（一名患者）或缺乏疗效（两名患者）退出研究。这些结果表明，伊拉地平在高血压患者中是一种有效且耐受性良好的β受体阻滞剂辅助药物。
